Associaçao da Videolaporoscopia e Quimioterapia Neoadjuvante no Tratamento do Carcinoma de Ovário. Uma Proposta Terapêutica: Relato de um Caso
DOI:
https://doi.org/10.32635/2176-9745.RBC.1994v40n4.3001Palabras clave:
Carcinoma de Ovário, VideolaparoscopiaResumen
O presente artigo constitui-se do relato de caso de uma paciente portadora de carcinoma de ovário estádio III (FIGO), que foi submetida à videolaparoscopia como primeira etapa do tratamento. Em virtude da dificuldade da realização de uma citorredução adequada, optou-se por quimioterapia neoadjuvante, seguida pela cirurgia citorredutora. Os autores apresentam os resultados obtidos, bem como a revisão bibliográfica sobre o assunto.
Descargas
Citas
CANIS M, CHAPRON C, MAGE G et al. Technique et résultats préliminaires du second-look per-coelioscopique dans les tumeurs épithéliales malignes de l'ovaire. J Gynecol Obstet Biol Reprod 1992; 21:655-663.
JANSON PO. Laparoscopic surgery - has the future got limits? Acta Obstet Gynecol Scand 1991; 70: 523-524. DOI: https://doi.org/10.3109/00016349109007910
NEZHATF, NE2HATC,WELANDER CE et al. Four ovarian cancers diagnosed during laparoscopic management of 1011 women with adnexal masses. Am J Obstet Gynecol 1992; 167: 790-796. DOI: https://doi.org/10.1016/S0002-9378(11)91591-9
NEZHAT C, NEZHAT F, SILFEN SL. Laparoscopic excision of ovarian neoplasms subsequentiy found to be malignant. Letter. Obstet and Gynecol 1991; 78:319-321.
VICENTE AM, SAINZ S, SORIANO G et al. Utilidad de Ia laparoscopia como método de “second-look” en Ias neoplasias de ovário. Rev Esp Enf Digest 1990; 77(4); 275-278.
LANGEBREKKE A, URNES A. Laparoscopic adnexectomy. Acta Obstet Gynecol Scand 1991; 70: 605-609. DOI: https://doi.org/10.3109/00016349109007925
METTLER L, CAESAR G, NEUNZLING S et al. The Value of Endoscopical Operated Ovarian Cysts at the Department of Obstetrics and Gynaecology at the University of Kiel in 1990 and 1991. Geburtsh U Frauenheilk 1993; 53: 253-257. DOI: https://doi.org/10.1055/s-2007-1023674
BERTELSEN K, BASTHOLT L. High-Dose Platinum Chemotherapy in Advanced Ovarian Câncer; A Phase 11 Study. Gynecol Oncol 1992; 44:79-82. DOI: https://doi.org/10.1016/0090-8258(92)90016-C
SEGNA RA, DATTINA PR, MANDELI JP et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993; 11(3): 434-39. DOI: https://doi.org/10.1200/JCO.1993.11.3.434
MORRIS M, GERSHENSON DM, WHm, ,T0N JT et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34(3): 334-388. DOI: https://doi.org/10.1016/0090-8258(89)90168-6
HOSKINS WJ, RUBIN SC, DULANEY E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34(3): 365-71. DOI: https://doi.org/10.1016/0090-8258(89)90175-3
MARKMAN M, HAKES T, REICHMAN B et al. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 1991; 9(2): 204-10. DOI: https://doi.org/10.1200/JCO.1991.9.2.204
MARKMAN M, ROWINSKY E, HAKES T et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncologic Group study. J Clin Oncol 1992; 10(9): 1485-91. DOI: https://doi.org/10.1200/JCO.1992.10.9.1485
MARKMAN M, REICHMAN B, HAKES T et al. Impact of survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 1992; 10(9): 1479-84. DOI: https://doi.org/10.1200/JCO.1992.10.9.1479
EISENHAUER EA, SWENERTON KD, STURGEON JF et al. Carboplatin therapy for recurrent ovarian carcinoma: National Center Institute of Canada experience and review of the literature. In: Carboplatin (JM-8): Current Prospectives and Future Directions. Philadelphia: W.B. Saunders, 1990; 133-140.
MARKMAN M, ROTHMAN R, HAKESTet al. Second-lineplatinum therapy In patients with ovarian câncer previousiy treated with cisplatin. J Clin Oncol 1991; 9{3): 389-93. DOI: https://doi.org/10.1200/JCO.1991.9.3.389
SAROSYG.KOHNE, LINKCet al. Taxol doseintensification (D.l.) In patients with recurrent ovarian câncer. Proceedings of the American Society of Clinical Oncology 1992; 11: A-716.
McGUIRE WP, ROWINSKY EK, ROSENHEIN NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111 (4); 273-79. DOI: https://doi.org/10.7326/0003-4819-111-4-273
EINZIG Al, WIERNIK PH, SASLOFF J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10(11): 1748-53. DOI: https://doi.org/10.1200/JCO.1992.10.11.1748
THIGPEN T, BLESSING J, BALL H et al. Phase II trial of taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncologic Group study. Proceedings of the American Society of Clinical Oncology 1990; 9: A-604,156.
SUTTON GP, BLESSING JA, HOMESLEY HD et al. Phase II trial of Ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7(11): 1672- 76. DOI: https://doi.org/10.1200/JCO.1989.7.11.1672
MARKMAN M, HAKEST, REICHMAN Betai. Ifosfamida and mesna in previousiy treated advanced epithelial ovarian câncer: activity in platinum-resistant disease. J Clin Onco 1992; 10(2); 243-48. DOI: https://doi.org/10.1200/JCO.1992.10.2.243
ROSEN GF, LURIAN JR, NEWTON M. Hexamethilmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol Oncol 1987; 27(2): 173-79. DOI: https://doi.org/10.1016/0090-8258(87)90290-3
MANETTAA, MacNElLLC, LYTER JAetal. Hexamethilmelamine as a single second-line agent in ovarian câncer. Gynecol Oncol 1990; 36(1): 93-96. DOI: https://doi.org/10.1016/0090-8258(90)90115-2
MOORE DH, FOWLER WC, JONES CP et al. Hexamethilmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol 1991; 165(3): 573-76. DOI: https://doi.org/10.1016/0002-9378(91)90287-2
VERGOTE I, HIMMELMANN A, FRANKENDAL B et al. Hexamethilmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47(3): 282-86. DOI: https://doi.org/10.1016/0090-8258(92)90127-5
HAUGE MD, LONG HG, HARTMANN LC et al. Phase II trial of intravenous hexamethilmelamine in patients with advanced ovarian cancer. Investigational New Drugs 1992; 10(40; 299-301. DOI: https://doi.org/10.1007/BF00944184
HATCH KD, BEECHAM JB, BLESSING JA et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 10F^ patients. Cancer 1991; 68(2): 269-71. DOI: https://doi.org/10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O
